Home » FlashRNA®

FlashRNA®

RNA delivery technology

Redefine the possibilities for cell & gene therapy, cell reprogramming, vaccine development, and beyond!

Discover the groundbreaking potential of FlashRNA®: a revolutionary viral vector that is changing the game of RNA delivery.

Thanks to its scalable production process, FlashRNA® is ready to use right through to therapy, supported by our GMP manufacturing platform.

Multiple or single RNA delivery

depending on your construct design

High RNA transfer efficacy

for in vivo and in vitro applications

Excellent safety profile

with high cell viability and phenotype preservation

a revolutionary viral vector technology for discovery and clinical applications

FlashRNA® is an RNA delivery system developed for all kinds of RNA therapy applications.

Regenerative medicine

Cell & Gene therapy
Gene editing (CRISPR-Cas9 systems, base editing)
Cell reprogramming

Find out more

Vaccination

Prophylactic vaccines
Therapeutic vaccines

Get more information

Performances of FlashRNA®

Enter the next generation of regenerative medicine / cell and gene therapy tools with FlashRNA®, our innovative technology for precise and efficient delivery of RNA molecules, designed for limitless possibilities*.

Efficacy

High transduction efficiency in any target cell in vitro & in vivo
High RNA delivery directly in the cell cytoplasm
Transient & high expression of your mRNA sequence(s)
Fast protein(s) expression within 4H post-transduction

DELIVERY CAPABILITY

High payload capacity: multiple RNAs either small or long
Delivery of distincts RNAs types such as mRNAs, guide RNAs, coding & non-coding RNAs…

Safety

No adverse immune response thanks to the biological origin of RNAs and the structure of the particles
No toxicity, the original cell phenotype and viability are preserved
RNA protected from degradation by the multi-layers structure of FlashRNA®

*Several development avenues are currently underway, including two main objectives: achieving cell specificity and extending the transient effect.

Scientific publications on FlashRNA® technology :

Prel A, Caval V, Gayon R, Ravassard P, Duthoit C, Payen E, Maouche-Chretien L, Creneguy A, Nguyen TH, Martin N, Piver E, Sevrain R, Lamouroux L, Leboulch P, Deschaseaux F, Bouillé P, Sensébé L, Pagès JC. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. Mol Ther Methods Clin Dev. 2015 Oct 21;2:15039. doi: 10.1038/mtm.2015.39. PMID: 26528487; PMCID: PMC4613645.

Mianné J, Nasri A, Nguyen Van C, Bourguignon C, Fieldès M, Ahmed E, Duthoit C, Martin N, Parrinello H, Louis A, Iché A, Gayon R, Samain F, Lamouroux L, Bouillé P, Bourdin A, Assou S, De Vos J. Efficient CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles. BMC Biol 20, 8. 2022. https://doi.org/10.1186/s12915-021-01214.

Creff J, Lamaa A, Benuzzi E, Balzan E, Pujol F, Draia-Nicolau T, Nougué M, Verdu L, Morfoisse F, Lacazette E, Valet P, Chaput B, Gross F, Gayon R, Bouillé P, Malloizel-Delaunay J, Bura-Rivière A, Prats AC, Garmy-Susini B. Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema. EMBO Mol Med. 2024 Feb;16(2):386-415. doi: 10.1038/s44321-023-00017-7. Epub 2024 Jan 2. PMID: 38177539; PMCID: PMC10898257.

collaboration opportunities

At FlashBiosolutions, we firmly believe in the power of collaborations to push the boundaries of innovation. We offer three unique collaboration models to maximize common synergies and fully leverage the potential of FlashRNA®:

Co-Development: As a biotech or pharmaceutical company, partner with us to co-develop groundbreaking RNA-based therapies and share in the intellectual property of the innovative products we create together.
Out-Licensing: Access our cutting-edge technology through a flexible licensing agreement that allows you to use FlashRNA® technology for the development of RNA-based therapies in a specific therapeutic area, indication, or for a specific target.
Proprietary Development: Entrust us with the complete development of your projects. Leveraging our expertise and infrastructure, we will internally develop your novel RNA-based therapy based on FlashRNA® technology. The resulting product’s IP will be fully owned by us.

Business director contact

Case studies

Discover how Flash BioSolutions is transforming the field with real-world examples such as RNA therapy for the treatment of Lymphedema. Click here to explore our case studies and see our innovations in action.

See all the case studies

News

Keep up with the latest advancements, updates, and breakthroughs in our field. Click here to explore our news page and stay informed about our progress and innovations.

See all the news